Intellia Therapeutics Inc. (NTLA) Stock
Key stats
- Market cap
- $1.60B
- Price / Earnings ratio
- -3.7x
- EPS (TTM)
- -$3.34
- Volume
- Loading
- 52-week high
- $18.48
- 52-week low
- $7.95
Source: third-party data provider, as of November 13, 2026
Compare with NTLA
Recent news
PRME, BEAM, EDIT, NTLA, CRSP Stocks Gain As FDA Signals Faster Route For Patient-Specific Gene Edits
PRME, BEAM, EDIT, NTLA, CRSP Stocks Gain As FDA Signals Faster Route For Patient-Specific Gene Edits
NTLA
4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch Now
4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch Now
NTLA
Cathie Wood-Led Ark Invest Sells AMD, SPCX, GOOG Stocks — But Loads Up On CMPS, NTLA, CRSP And Other Healthcare Firms
Cathie Wood-Led Ark Invest Sells AMD, SPCX, GOOG Stocks — But Loads Up On CMPS, NTLA, CRSP And Other Healthcare Firms
NTLA
Intellia Therapeutics (NTLA) Soars 7.6%: Is Further Upside Left in the Stock?
Intellia Therapeutics (NTLA) Soars 7.6%: Is Further Upside Left in the Stock?
NTLANews tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 46.38
- MACD 12/26/9
- -0.14
- EMA 9 of MACD
- -0.07
- MACD histogram
- -0.07
- SMA 50
- $12.02
- Price below SMA 50
- EMA 50
- $12.04
- Price below EMA 50
- SMA 200
- $12.99
- Price below SMA 200
- EMA 200
- $12.29
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of -$0.98 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news
PRME, BEAM, EDIT, NTLA, CRSP Stocks Gain As FDA Signals Faster Route For Patient-Specific Gene Edits
PRME, BEAM, EDIT, NTLA, CRSP Stocks Gain As FDA Signals Faster Route For Patient-Specific Gene Edits
NTLA4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch Now
4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch Now
NTLACathie Wood-Led Ark Invest Sells AMD, SPCX, GOOG Stocks — But Loads Up On CMPS, NTLA, CRSP And Other Healthcare Firms
Cathie Wood-Led Ark Invest Sells AMD, SPCX, GOOG Stocks — But Loads Up On CMPS, NTLA, CRSP And Other Healthcare Firms
NTLAIntellia Therapeutics (NTLA) Soars 7.6%: Is Further Upside Left in the Stock?
Intellia Therapeutics (NTLA) Soars 7.6%: Is Further Upside Left in the Stock?
NTLACathie Wood Loads Up On These Biotech Stocks After Strong Rallies – Unloads $18M Worth Of TWST Shares
Cathie Wood Loads Up On These Biotech Stocks After Strong Rallies – Unloads $18M Worth Of TWST Shares
NTLA
CRSP, NTLA, BEAM, PRME, EDIT Shares Slip — Did Claude Just Spook Gene-Editing Stocks?
CRSP, NTLA, BEAM, PRME, EDIT Shares Slip — Did Claude Just Spook Gene-Editing Stocks?
NTLA
Intellia Eyes Lonvo-z Launch as HAE PDUFA Nears, TTR Study Advances
Intellia Eyes Lonvo-z Launch as HAE PDUFA Nears, TTR Study Advances
NTLA
Can Intellia's Pipeline Progress Create Long-Term Value Amid Rivalry?
Can Intellia's Pipeline Progress Create Long-Term Value Amid Rivalry?
NTLA
FDA Accepts & Gives Priority Review to Intellia's BLA for HAE Drug
FDA Accepts & Gives Priority Review to Intellia's BLA for HAE Drug
NTLA
3 Promising Genomics Stocks in the Spotlight in 2026
3 Promising Genomics Stocks in the Spotlight in 2026
NTLANews tone: automated (AI) classification of the article's content, not a price prediction.
About Intellia Therapeutics Inc.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. John M. Leonard M.D. | President, CEO & Director | 1957 |
| Mr. Edward J. Dulac III | Executive VP, CFO & Treasurer | 1975 |
| Dr. Birgit Schultes Ph.D. | Executive VP & Chief Scientific Officer | 1963 |
| Mr. James E. Basta Esq., J.D. | Executive VP, General Counsel & Corporate Secretary | 1966 |
| Dr. Rachel E. Haurwitz Ph.D. | Co-Founder | 1986 |
| Dr. Jennifer A. Doudna Ph.D. | Founder & Member of Scientific Advisor Board | 1964 |
| Dr. Derrick J. Rossi Ph.D. | Founder & Member of Scientific Advisor Board | — |
| Dr. Rodolphe Barrangou M.B.A., Ph.D. | Founder & Member of Scientific Advisor Board | — |
| Prof. Luciano Marraffini Ph.D. | Founder & Member of Scientific Advisor Board | — |
| Mr. Erik J. Sontheimer Ph.D. | Founder & Member of Scientific Advisor Board | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 46.38
- MACD 12/26/9
- -0.14
- EMA 9 of MACD
- -0.07
- MACD histogram
- -0.07
- SMA 50
- $12.02
- Price below SMA 50
- EMA 50
- $12.04
- Price below EMA 50
- SMA 200
- $12.99
- Price below SMA 200
- EMA 200
- $12.29
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $8.00
- Average
- $19.00
- High
- $30.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -13.9 | +10.6 | ||||||||||
| 2022 | -20.5 | -1.0 | -9.0 | -35.6 | -10.6 | +20.8 | +19.9 | -4.3 | -6.7 | -5.5 | -3.3 | -23.8 |
| 2023 | +22.5 | -6.9 | -8.5 | +1.8 | -1.3 | +6.9 | +4.0 | -8.5 | -16.1 | -14.8 | +16.2 | -1.1 |
| 2024 | -22.7 | +27.2 | -15.8 | -21.4 | -5.0 | -4.8 | +16.6 | -10.7 | -4.9 | -25.9 | +5.5 | -25.9 |
| 2025 | -15.5 | +5.8 | -24.8 | +33.2 | -20.5 | +31.0 | +17.8 | -1.1 | +51.5 | -32.7 | -31.2 | +6.8 |
| 2026 | +42.8 | +5.5 | -17.0 | +1.6 | +6.1 | +23.2 | -38.1 | +18.2 | -5.0 | +2.9 | -2.1 |
